An interventional study of Fluobeam LX, Fluoptics, Grenoble, France in Autofluorescence, Thyroidectomy and Hypoparathyroidism, sponsored by Regional Hospital West Jutland. Completed at 2 sites in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-03.
Sponsored by Regional Hospital West Jutland · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Hypoparathyroidism with a site in Denmark — 3 open to participants now, 6 under way, 2 of them phase 3. Hypoparathyroidism · Denmark.
Among the 21 studies in Hypoparathyroidism with a site in Denmark, this one is the 8th largest by enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2021, is one of 5 with no phase, and was the 13th registered.
128 studies on the registry are indexed under Hypoparathyroidism; 30 are open to participants now.
Browse Hypoparathyroidism studies →3 of the 21 studies in Hypoparathyroidism with a site in Denmark are open now. Recruiting first, the newest first:
Lars Rejnmark · Sites in Denmark
Ages 18+
Aarhus University Hospital · Sites in Denmark
Ages 18+
Aarhus University Hospital · Sites in Denmark
Ages 18+
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 26 Hypoparathyroidism studies recruiting now, 19 (73%) set no upper age limit and 5 (19%) stop at 75 or younger; 5 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 3 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 78 is above the median of 50 across 77 interventional studies indexed under Hypoparathyroidism.
Median enrollment 78 across the 15 interventional studies, 100 across the 6 observational. Of the 14 that completed or were terminated, 6 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 21 have an industry lead sponsor. The 10 most frequent:
Regional Hospital West Jutland is the lead sponsor of 11 studies on the registry; 3 are open to participants now.
Regional Hospital West Jutland has 1 study filed under Hypoparathyroidism — fewer than ten, so there is no comparison to draw.
2 of the studies in Hypoparathyroidism with a site in Denmark that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06222606Aarhus University HospitalSurgery for Thyroid Cancer With or Without Autofluorescence to Prevent Hypoparathyroidism | 2027-01 |
| NCT07381998Aarhus University HospitalEffects of Total Thyroid Removal on Parathyroid Function and Quality of Life | 2027-07 |
Add all 2 to your calendar (.ics) → With an account.
Among the 21 studies in Hypoparathyroidism with a site in Denmark, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Hypoparathyroidism is the most frequent complication in total thyroidectomy. The use of near-infrared autofluorescence (NIRAF) intraoperatively, seems to reduce the rate of transient hypoparathyroidism. Unfortunately, no effect on permanent hypoparathyroidism has been shown.
In order to cover every aspect of the impact of NIRAF in thyroid surgery, an evaluation in low-volume, non-parathyroid institutions is needed. This is the overall aim of our current studies. The objective of this specific study is to evaluate the impact of NIRAF on immediate, transient and permanent hypoparathyroidism following total thyroidectomy in low-volume, non-parathyroid institutions.
Patients referred for total thyroidectomy will undergo NIRAF-assisted surgery (Fluobeam LX) at two low-volume ENT-departments with no experience in parathyroid surgery.
PTH and ionized calcium will be assessed preoperatively, on postoperative day 1 (POD1) and minimum two months following surgery. Patients who still fulfill the criteria for hypoparathyroidism at that point will be followed until one year following surgery. The rates of immediate, transient and permanent hypoparathyroidism will be assessed and compared to a historic cohort.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients undergoing NIRAF-assisted total thyroidectomy
Device: Fluobeam LX, Fluoptics, Grenoble, France
See arm description
Rate of hypoparathyroidism
Time frame: Will be assessed on postoperative day one, minimum two months and one year following surgery.
Parathyroid gland identification rate
Time frame: Will be assessed at the time of surgery
Parathyroid autotransplantation rate
Time frame: Will be assessed at the time of surgery
Rate of inadvertently excised parathyroid glands
Time frame: Will be assessed 1 month following surgery
Plan to share: No
No publications or documents are linked to this record.
Ran from Sep 2021 to primary completion in Dec 2023, 26 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Regional Hospital West Jutland